Glass House Brands (GLAS) Non-Current Debt (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Non-Current Debt of $67.8 million for Q1 2026, up 3.07% year-over-year from $65.8 million in Q1 2025, and down 1.18% quarter-over-quarter from $68.6 million in Q4 2025.
Glass House Brands (GLAS) Non-Current Debt (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Non-Current Debt for 7 consecutive years, with $67.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 3.07% year-over-year to $67.8 million; the TTM figure through Mar 2026 stood at $67.8 million (up 3.07% YoY), while the FY2025 annual figure was $68.6 million, up 35.76% from the prior year.
- Non-Current Debt declined to $67.8 million in Q1 2026 per GLAS's latest filing, from $68.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $68.8 million in Q3 2025 and bottomed at $45.1 million in Q1 2022.
- Historically, Non-Current Debt has averaged $60.4 million across 5 years, with a median of $62.6 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 30048.31% — and 2024, when it fell 18.27%.
- Glass House Brands' Non-Current Debt stood at $62.6 million in 2022, then fell by 9.75% to $56.5 million in 2023, then slipped by 10.55% to $50.6 million in 2024, then surged by 35.76% to $68.6 million in 2025, then retreated by 1.18% to $67.8 million in 2026.
- Business Quant data shows GLAS's Non-Current Debt at $67.8 million in Q1 2026, $68.6 million in Q4 2025, and $68.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 130.00 Mn |
| 10 | Glass House Brands | 828.45 Mn | 809.90 Mn | 15.77 Mn | 55.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.82 Mn |
| Dec 31, 2025 | 68.63 Mn |
| Sep 30, 2025 | 68.81 Mn |
| Jun 30, 2025 | 65.85 Mn |
| Mar 31, 2025 | 65.80 Mn |
| Dec 31, 2024 | 50.55 Mn |
| Sep 30, 2024 | 52.20 Mn |
| Jun 30, 2024 | 53.70 Mn |
| Mar 31, 2024 | 54.88 Mn |
| Dec 31, 2023 | 56.51 Mn |
| Sep 30, 2023 | 63.87 Mn |
| Jun 30, 2023 | 63.63 Mn |
| Mar 31, 2023 | 62.89 Mn |
| Dec 31, 2022 | 62.62 Mn |
| Sep 30, 2022 | 62.41 Mn |
| Jun 30, 2022 | 61.89 Mn |
| Mar 31, 2022 | 45.07 Mn |
| Dec 31, 2021 | 44.82 Mn |
| Sep 30, 2021 | 207,000.00 |
| Jun 30, 2021 | 217,000.00 |